Safety of Mesenchymal Stem Cells Therapy in Patients with Inflammatory Bowel Diseases – 5 Year Follow-Up

Knyazev Oleg Vladimirovich,*, Parfenov Asfodl Ivanovich, Konoplyannikov Anatolyi Georgievich, Kagramanova Anna Valeryevna**, Churikova Alevtina Alekseevna, Ruchkina Irina Nikolaevna, Lishinskaya Albina Aleksandrovna, Boldireva Oksana Nikolaevna and Fadeeva Nina Aleksandrovna

1Central Research Institute of Gastroenterology, Department of Treatment Inflammatory Bowel Diseases, Russia
2Central Research Institute of Gastroenterology, Department of Intestinal Pathology, Russia
3Central Research Institute of Gastroenterology, Department of Experimental Radiotherapy, Russia
4Candidate of Science, Scientist Researcher, Russia

Abstract

Aim: To compare safety profile of therapy in patients with ulcerative colitis (UC) and Crohn disease (CD), receiving anti-inflammatory therapy, using bone marrow-derived mesenchymal Stromal cells (MSC) and standard therapy with 5-aminosalicylic acid (5-ASA), glucocorticosteroids (GCS) and immunosuppressive agents (IS).

Materials and methods: Adverse events were analyzed in 103 patients with inflammatory bowel disease (IBD) after administration MSCs (56 patients UC and 47 patients CD). The findings were compared with data obtained in 208 patients with UC and CD, receiving standard anti-inflammatory therapy. All analyzed patients were similar in demographic characteristics, the duration of disease, the extent of disease, course of disease, phenotype and degree of disease.

The analyzed groups did not include patients, treated with anti-TNF therapy. The safety of therapy was evaluated by presence of complications, developed during follow-up period.

Results: We conducted analysis of side effects in 103 IBD patients, treated with mesenchymal stem cells, comparing with 208 UC and CD patients, treated with standard anti-inflammatory therapy and finally we did not reveal any differences in developing acute post-transfusional toxicity, infectious complications, exacerbation of chronic inflammatory diseases, serious infectious complications, malignancy and death in UC and CD patients, besides transite febrile.

Conclusion: Results of our study show that innovative method of cell therapy is safe in clinical practice.

Keywords: Safety of cell therapy; Mesenchymal Stromal cells; Crohn disease; Ulcerative colitis; Inflammatory bowel diseases

Aim of Study

To compare safety profile of therapy in patients with ulcerative colitis (UC) and Crohn disease (CD), receiving anti-inflammatory therapy including MSC and standard therapy, including 5-ASA, Glucocorticosteroids (GCS) and immune-suppressive therapy.

Introduction

Mesenchymal Stromal cells (mesenchymal Stem cells; MSC) are a heterogeneous group of cells, that can be isolated from many tissues (bone marrow, adipose tissue, dental pulpe). First described in 1960-years of XX century [1], MSC have recently received attention in a number of different clinical fields for their potential therapeutic effects.

Although often described as «adult stem cells», MSC's have limited cellular differentiation ability. Instead, pre-clinical evidence suggests that MSCs exert their beneficial effects largely through immunomodulatory and paracrine mechanisms. MSCs home to sites of inflammation and secrete bioactive molecules, and thus may be especially effective in different pro-inflammatory diseases [2].

There is a growing body of literature demonstrating the efficacy of MSC therapy in a variety of pre-clinical models, including acute lung injury [3,4], septic shock [5], acute myocardial infarction [6]. Several small clinical trials have investigated efficacy and safety of MSCs in diseases including chronic heart failure, acute myocardial infarction, hematological malignancies, Crohn disease [7] and graft-versus-host disease.

However, safety concerns represent a significant barrier to the successful translation of MSCs into an acceptable clinical therapeutic. Potential risk is associated with its proliferative capacity, susceptibility to infectious complications given their immune-suppressive effects, embolism of the cells, zoonoses associated with cell culture reagents, and acute or chronic immunogenility of the cells themselves [8].

Therefore, we conducted a systematic review of randomized and non-randomized controlled trials as well as uncontrolled clinical trials in foreign literature that examined the safety and efficacy of intravascularly delivered MSCs, and revealed their most frequent adverse events [9]. Adverse events were grouped according to the immediacy of the event - acute infusional toxicity, fever, the occurrence of...
organ system complications (neurological, pulmonary, cardiovascular, gastrointestinal and renal, and hematologic systems), infection, and the occurrence of longer term adverse effects (death, malignancy).

Included studies were conducted in 14 different countries from Asia, the Middle East, Europe, and North America. There were eight RCTs (n=369 patients) [10-17], 10 non–RCTs (n=466 patients) [18-27] and 18 uncontrolled clinical trials (n=252 patients) [28-45]. Six of 36 studies were multi-center [12,13,20,23,32,33]. One non-controlled study had a mixed adult-pediatric population [39], all other studies included only adult participants. The follow-up period was reported in all studies and the duration ranged from 0.5 to 60 months.

There were following diseases analyzed: eight randomized controlled studies included patient populations with cardiovascular diseases-acute myocardial infarction [11,12], chronic heart failure [10,16], with neurological disease either ischemic stroke [13], spinal cord injury [17], following stem cell transplantation for hematological malignancies [15]. The 10 non–RCTs included patient populations with old myocardial infarctions [25], stem-cell transplant post renal transplant [27], stem cell transplant for hematological malignancy [18,19,23], graft-versus-host disease [20,26], or healthy volunteers [24].

Sixteen studies used autologous MSC [10,11,13,14,16,17,22,24,25,27,29,31,32,37,45], eight used allogenic MSC [12,18,20,34,35,39,40,41]. Nine of the 36 studies cryopreserved MSCs prior to administration [12,18,20,21,23,29,31,32,44], and one study used both fresh and cryopreserved MSC [33], while the remainder of studies used only fresh MSCs. A meta-analysis revealed no significant differences in the occurrence of acute infusional toxicity, infectious complications, recurrence of chronic inflammatory diseases, serious infectious complications, malignancy and death between patients treated with MSC and control group. Significant association was demonstrated between MSC injection and transient fever.

Further we demonstrate our data for safety profile of allogenic mesenchymal stromal bone marrow cells in patients with inflammatory bowel diseases over a 5-year follow-up period.

Materials and Methods

Systemic transplantation of allogenic bone marrow MSC was performed in 74 UC and 64 CD patients ranging from 2008 to 2014 years.

First analysed group included 56 UC patients, follow-up period comprised in median 62 ± 4 months. This group consists of 29 (51.78%) man and 27 (48.22%) women (Table 1). Mean age was 35.4 ± 1.42 years. The second control group included 84 UC patients, receiving standart anti-inflammatory therapy with 5-ASA and GCS. This group consists of 46 (54.8%) man and 38 (45.2%) women. Mean age – 34.98 ± 1.23 years.

Third group included 47 CD patients; mean follow-up period was 64 ± 4 months. Nineteen (40.4%) man and twenty-eight (59.6%) women were included in the third group. Mean age was 30.4 ± 1.2 years. Fourth control group consisted of 124 CD patients, receiving standard anti-inflammatory therapy including 5-ASA, GCS and IS. In this group were 65 (54.2%) man and 68 (45.8%) women. Mean age was 36.8 ± 1.5 years.

We did not include patients, receiving anti-TNF therapy, in analysed groups.

Technique of receiving and cultivation MSC in an appropriate for systemic transplantation amount (150-200 millions of cells) was published [46]. This method is validated by Federal Supervisory Agency for Health Care and Social Development Ministry of Healthcare and Social Development of the Russian Federation (License 2006/206). Bone marrow cells were isolated by means of flushing the sternum or iliac crest of healthy donor under local anesthesia and aseptic conditions. All donors signed informed consent for using bone marrow samples for scientific purposes. MSC culture was injected intravenous drip-feed in dosage 1,5-2 ml/ kg body weight. For systemic transplantation 130-160 mln allogenic MSC, cultivated, were suspended in 200 ml sterile isotonic solution, consisting of heparin in concentration 50 U/ml. MSC culture was injected during 40-60 minutes by means of intravenous drip-feed infusion. Mathematical modeling of MSC treatment was performed to assess maximal efficacy and minimal side effects of MSCs. We analyzed several trials, in which regimen of MSC administration, frequency and the rationale for the cell dose were examined [13,14,14,44,45]. All patients signed informed consent for participating in study before MSC injection. Thus, procedure of MSC cultivation was performed according GMP.

Safety of therapy was assessed by presence of complications, occurred during follow-up period, for example acute infusional toxicity, fever; complications (neurological, pulmonary, cardiovascular (arrhythmias, etc.), urinary, gastrointestinal tract and blood system), infection complications, exacerbation of chronic inflammatory diseases, serious infectious complications (pneumonia, sepsis, abscess), malignancy, death. All persons, monitoring the complications were blinded with the treatment.

Results and Discussion

In the first group 3/56 UC patients (5.4%) have acute infusional toxicity–looks like hives immediately or after MSC injection, in the second group allergic reaction like popular urticaria was noticed in 1/84 (1.2%) patient, treated with sulfasalazin. Allergic reaction like hives in first group patients had no statistical significance in compare with second group of patients (x²=0.35; p=0.87). In 16/56 (28.6%) patients of first group were noted increasing of temperature around 37.2-37.4°C during 12 hours after MSC injection or fever around 38.0°C in 1/84 (1.2%) patients of second group was reported increasing temperature above 37.7°C, caused by intravenous injection of prednisolon. Fever and temperature increasing after MSC injection were statistically significant compared to control group – relative risk (RR) was 24.0 (95% CI 3.27 - 175.89); x²=21.12; p=0.0000043. In the first UC group non-serious infectious complications and exacerbation of chronic inflammatory diseases were revealed in 7/56 (12.5%) patients, in second group - in 14/84 (16.7%) patients. There was no significant difference in risk of infectious complications and exacerbation of chronic inflammatory diseases between two groups of UC patient, receiving standard anti-inflammatory therapy and MSC (RR-0.75; 95%CI 1.5-23.58; x²=0.16; p=0.66). In the first group serious infectious complications (pneumonia, pleurisy, activation of latent tuberculosis) were detected in 1/56 patients (1.8%), in the second – in 5/84 (5.9%). There was no difference in this complications between two groups (RR-0.3; 95%CI 0.04-2.5; x²=0.59; p=0.44). Colorectal cancer was documented only in 1/56 (1.8%) patient in the first group. Diagnosis of colon cancer was established in 10 days after MSC injection (Table 2).

<table>
<thead>
<tr>
<th>Patient</th>
<th>Male–to–female ratio (%)</th>
<th>Mean Age, years</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 group (n=56)</td>
<td>29.27 (51.48)</td>
<td>35.4 ± 1.42</td>
</tr>
<tr>
<td>2 group (n=84)</td>
<td>46.38 (54.45)</td>
<td>34.98 ± 1.23</td>
</tr>
<tr>
<td>3 group (n=47)</td>
<td>19.28 (40.59)</td>
<td>30.4 ± 1.2</td>
</tr>
<tr>
<td>4 group (n=124)</td>
<td>56.68 (45.54)</td>
<td>36.8 ± 1.5</td>
</tr>
</tbody>
</table>

Table 1: Demographic characteristics of patients with CD and UC.
During five-year follow-up period malignancy was found in 4/84 (4,8%) in the second group (RR=0.5, 95%CI 0.05-4.96; x²=0.01; p=0.97). In the first and in the second groups during five-year follow-up one lethal case from each group was documented and it was 1,8% and 1,2%, respectively (RR=1.5; 95%CI 0.1-23.49; x²=0.01; p=0.66).

In the third group of CD patients acute infusional toxicity like hives and Quincke’s edema were detected in 2/47 patients (4,2%) immediately after MSC injection, in the fourth group there were no complications during anti-inflammatory therapy, but these manifestations have no statistically significance between groups (x²=2.3, p=0.07). Increase in body temperature up to 37.2-37.4°C during 12 hours after MSC injection or fever up to 38.0°C was noticed in 22 patients of third group (46,8%), in the fourth group of patients there was no fever, associated with intravenous interventions (medication injection) or per os administration was found in 0/124 (0%). Fever and mild increase of temperature after MSC injection were statistically significant compare to control group – RR = 58.5 (95% CI 8.1: 422.0; x²=8.3; p=0.01). Non-serious infectious complications and exacerbation of chronic inflammatory diseases during therapy observed in 12 patients of 47 in the third group, that accounts 25,5%, in the fourth group-in 4/84 (4,8%) of patients of 47, that had no significant difference: RR = 0.62 (95% CI 0.39 - 1.15), x²=1,86, p=0.17 (Table 3).

There were no differences between third and fourth groups in risk of serious infectious complications (pneumonia, peuris; activation of latent tuberculosis) during standard anti-inflammatory CD therapy and therapy with MSC. In the third group one patient developed pneumonia 1/47 (2,1%) in the fourth group two cases of pneumonia and one case of latent tuberculosis activation were detected – 3/124 (2,4%) (RR=0.88, 95%CI 0.09-1.85; x²=0.21; p=0.7).

In the third group of CD patients no cases of colorectal cancer were found. In the third group during five-year follow-up period no lethal outcomes were documented, in the fourth group one lethal case (0,8%), unlinked to underlying disease was found (x²=0.26; p=0.61). In the fourth group malignant transformation was noted in 2 patients (1,6%) from 124 (x²=0.01; p=0.93).

In patients with UC and CD, receiving MSC treatment, no cardiovascular, pulmonary, neurological, renal, and hematologic systems complications were detected.

### Table 2: Summary analysis of side effects in UC patients, receiving MSC and in control group.

<table>
<thead>
<tr>
<th>Side effects in all analyzed clinical trials</th>
<th>Frequency in 1 group UC patients</th>
<th>Frequency in 2 group UC patients</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute infusion reaction</td>
<td>3/56</td>
<td>1/84</td>
<td>0.48-42.18</td>
<td>0.87</td>
</tr>
<tr>
<td>Fever</td>
<td>16/56</td>
<td>1/84</td>
<td>3.27-175.89</td>
<td>0.0000043</td>
</tr>
<tr>
<td>Serious infectious complications</td>
<td>1/56</td>
<td>5/84</td>
<td>0.04-2.5</td>
<td>0.44</td>
</tr>
<tr>
<td>Non-serious infectious complications</td>
<td>7/56</td>
<td>14/84</td>
<td>1.5-23.58</td>
<td>0.66</td>
</tr>
<tr>
<td>Malignancy</td>
<td>1/56</td>
<td>4/84</td>
<td>0.05-4.96</td>
<td>0.97</td>
</tr>
<tr>
<td>Lethal cases</td>
<td>1/56</td>
<td>1/56</td>
<td>0.1-23.49</td>
<td>0.66</td>
</tr>
</tbody>
</table>

### Table 3: Summary analysis of side effects occurred after MSC injection and in control group of patients with CD.

<table>
<thead>
<tr>
<th>Side effects in all analysed clinical trials</th>
<th>Frequency in 3 group CD patients</th>
<th>Frequency in 4 group CD patients</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute infusion reaction</td>
<td>2/47</td>
<td>0</td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>22/47</td>
<td>0</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Serious infectious complications</td>
<td>1/47</td>
<td>3/124</td>
<td>0.09-1.85</td>
<td>0.7</td>
</tr>
<tr>
<td>Non-serious infectious complications</td>
<td>12/47</td>
<td>48/124</td>
<td>1.5-23.58</td>
<td>0.66</td>
</tr>
<tr>
<td>Malignancy</td>
<td>0</td>
<td>2/124</td>
<td>-</td>
<td>0.93</td>
</tr>
<tr>
<td>Lethal cases</td>
<td>0</td>
<td>1</td>
<td>-</td>
<td>0.81</td>
</tr>
</tbody>
</table>

**Conclusion**

Our study includes comparative analysis of adverse events, associated with MSC treatment and standard anti-inflammatory therapy in UC and CD patients. We analyzed advanced outcomes in 103 IBD patients, receiving MSC therapy and compared this data with 208 UC and CD patients, who had the same demographic characteristics, disease duration, extent of disease, course of disease, phenotype of disease, type of severity. Thus we did not observe any significant differences in MSC safety, aside from transient fever.

This analysis did not reveal any differences in acute post-transfusional toxicity, infectious complications, exacerbation of chronic inflammatory diseases, serious infectious complications, malignancy and lethal cases in UC and CD patients, treated with standard anti-inflammatory therapy.

We have detected significant association between MSC injection and fever. However, fever was transient and not associated with long term sequelae. The mechanisms for fever are not clear but could be related to acute inflammatory reactions by a subset of patients to particular preparations of MSCs, not unlike similar reactions occasionally observed with red blood cell and fresh frozen plasma administration [47].

Although malignant transformation is a theoretical risk, our own experience and literature analysis, presented in this review found no association between MSCs and tumour formation. Concerns related to tumorigenicity of MSCs were raised by preclinical studies demonstrating increased tumour burden in vivo [48]. Although recent position papers have suggested low probability of malignant transformation and tumour formation with MSCs [8]. Malignancy occurred only in studies involving participants with ongoing or previous malignancies; no de novo malignancies were observed.

Although MSC immunomodulatory effects may be beneficial in pro-inflammatory diseases, these same effects may leave a patient susceptible to infection [49]. The question arises-whether immunosuppressive therapy could increase risk of infections? This review did not demonstrate any evidence of increased susceptibility to infections with MSC administration.

In our review, infections were common in already immunosuppressed patients (e.g., following hematopoietic stem cell transplant), however the infection rates were similar to those in control group of patients [47].
Currently obtained data show that despite of strong immunosuppressive effect due to autoimmune aggression, MSC did not hinder the activity of immunocompetent cells, directed against infectious agents [50,51].

Absence of post-transfusional reaction may be explained by low MSC immunogenicity, due to absence HLA class II and low level of expression HLA I class at their surface. The use of fetal bovine serum for cultivating MSCs could be one of the reasons for above mentioned post-transfusional toxicity, and another potential concern with MSC therapy application is the use of dimethyl sulfoxide as cryopreservative, which has toxic side effects and could cause hypersensitivity reactions. Thus, greater vigilance may be needed in future studies for reporting cellular viability and monitoring for potential dimethyl sulfoxide related adverse events. Results from our study should provide some assurance to investigators and health regulators that with the present evidence, this innovative therapy appears safe.

References